Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City

Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw 
Global Investment Conference in New York City September
8-10th 
CAMBRIDGE, MA -- (Marketwired) -- 09/03/13 --   Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will
be featured as a presenting company at the 15th Annual Rodman &
Renshaw Global Investment Conference. The conference, sponsored by
H.C. Wainwright & Co., LLC, is being held September 8-10, 2013, at
the Millennium Broadway Hotel in New York City. 
Terrence W. Norchi, MD, CEO of Arch Therapeutics, will provide an
overview of the Company's business during the live presentation and
will be available to participate in one-on-one meetings with
investors who are registered to attend the conference.  
If you are an institutional investor, and would like to attend the
Company's presentation, please click on the following link
(www.rodm.com) to register for the Rodman & Renshaw conference. Once
your registration is confirmed, you will be prompted to log into the
conference website to request a one-on-one meeting with the Company. 
Follow the official Rodman & Renshaw handle on Twitter @Rodman_2013
and use #Rodman2013 for conference information and updates.  
Event: 15th Annual Rodman & Renshaw Global Investment Conference 
Date: Tuesday September 10, 2013 
 Time: 8:45am (Eastern Time)  
Location: Room 7.02 (7th floor); Millennium Broadway Hotel in New
York City 
The presentation will be webcast live. To access the webcast, please
visit:
 http://wsw.com/webcast/rrshq23/ARTH.  
The webcast replay will remain available for 90 days following the
live presentation. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
(OTCQB: ARTH) is a medical device company developing a novel approach
to stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch's goal is to develop and commercialize
products based on our innovative technology platform that make
surgery and interventional care faster and safer for patients. Arch's
flagship development stage product candidate known as AC5(TM) is
being designed to elegantly achieve hemostasis in minimally invasive
and open surgical procedures. Find out more at
www.archtherapeutics.com.  
About Rodman & Renshaw Conferences, LLC
 The Rodman & Renshaw Annual
Global Investment Conference is an informational service and
networking opportunity for companies and investors. Rodman does not
prepare, review or edit the presentations and other information
provided by each company, and does not take any responsibility for
the accuracy or adequacy of any such information as the basis for any
investment decision. Rodman is not providing any person with any
investment advice through their participation in or attendance of the
Conference, nor is Rodman soliciting any offers to buy or sell any
security of any company. 
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at
www.sec.gov. 
On Behalf of the Board,
 Terrence W. Norchi, MD.
 Arch Therapeutics,
Inc. 
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com 
Website: www.archtherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.